Efficacy of Drug-Coated Balloon Angioplasty in Pulmonary Vein Stenosis or Total Occlusion.
JACC Clin Electrophysiol
; 2024 Jun 03.
Article
de En
| MEDLINE
| ID: mdl-38904577
ABSTRACT
BACKGROUND:
Current therapies for pulmonary vein stenosis (PVS) or pulmonary vein total occlusion (PVTO) involving angioplasty and stenting are hindered by high rates of restenosis.OBJECTIVES:
This study compares a novel approach of drug-coated balloon (DCB) angioplasty and stenting with the current standard of care in PVS or PVTO due to pulmonary vein isolation (PVI).METHODS:
A retrospective single-center study analyzed patients with PVS or PVTO due to PVI who underwent either angioplasty and stenting (NoDCB group; December 2012-December 2016) or DCB angioplasty and stenting (DCB group; January 2018-January 2021). Multivariable Andersen-Gill regression analysis assessed the risk of restenosis and target lesion revascularization (TLR).RESULTS:
The NoDCB group comprised 58 patients and 89 veins, with a longer median follow-up of 35 months, whereas the DCB group included 26 patients and 33 veins, with a median follow-up of 11 months. The DCB group exhibited more PVTO (NoDCB 12.3%; DCB 42.4%; P = 0.0001), with a smaller reference vessel size (NoDCB 10.2 mm; DCB 8.4 mm; P = 0.0004). Follow-up computed tomography was performed in 82% of NoDCB and 85% of DCB, revealing lower unadjusted rates of restenosis (NoDCB 26%; DCB 14.3%) and TLR (NoDCB 34.2%; DCB 10.7%) in the DCB group. DCB use was associated with a significantly lower risk of restenosis and TLR (HR 0.003 CI 0.00009-0.118; P = 0.002).CONCLUSIONS:
The novel approach of DCB angioplasty followed by stenting is effective and safe and significantly reduces the risk of restenosis and reintervention compared with the standard of care in PVS or PVTO due to PVI.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
JACC Clin Electrophysiol
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique